In prostate cancer, PSMA-targeted imaging outperforms conventional modalities: 99mTc-PSMA SPECT/CT achieves 80% sensitivity and 100% specificity for bone metastases, detecting lesions ≤0.6cm that 99mTc-MDP misses, and altering management in 14.9% of patients (71). This evidence concerns the gene FOLH1 and prostate cancer.